These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 28526719

  • 1. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A, Tsai K.
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [Abstract] [Full Text] [Related]

  • 2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 3. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [Abstract] [Full Text] [Related]

  • 4. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 5. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.
    Eur J Cancer; 2018 Sep 01; 101():229-235. PubMed ID: 30096703
    [Abstract] [Full Text] [Related]

  • 6. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, Sperandi F, Piraccini BM.
    Eur J Dermatol; 2016 Jun 01; 26(3):232-9. PubMed ID: 27019511
    [Abstract] [Full Text] [Related]

  • 7. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Sibaud V, Baric L, Cantagrel A, Di Palma M, Ederhy S, Paques M, Perlemuter G.
    Bull Cancer; 2021 May 01; 108(5):528-543. PubMed ID: 33812673
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A, Jain P, Fradley MG, Lenihan D, Gutierrez JM, Jain C, de Lima M, Barnholtz-Sloan JS, Oliveira GH, Dowlati A, Al-Kindi S.
    Cancer Med; 2021 Jun 01; 10(12):3862-3872. PubMed ID: 33982883
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I, Zorzetto L, Frigo AC, Chiarion Sileni V, Alaibac M.
    Eur J Dermatol; 2017 Oct 01; 27(5):482-486. PubMed ID: 29084636
    [Abstract] [Full Text] [Related]

  • 10. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A, Gill J, Kamra S, Chen L, Ahuja A.
    J Hematol Oncol; 2017 Jan 04; 10(1):3. PubMed ID: 28052762
    [Abstract] [Full Text] [Related]

  • 11. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM, Long GV.
    Clin Cancer Res; 2014 Apr 15; 20(8):2035-43. PubMed ID: 24583796
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
    Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.
    Cancer; 2019 Mar 15; 125(6):884-891. PubMed ID: 30521084
    [Abstract] [Full Text] [Related]

  • 19. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.
    Lancet Oncol; 2014 Aug 15; 15(9):954-65. PubMed ID: 25037139
    [Abstract] [Full Text] [Related]

  • 20. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.
    Lancet Oncol; 2018 May 15; 19(5):603-615. PubMed ID: 29573941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.